Striking senescence with sodium transporter inhibition.
Abstract
Senescence is associated with multiple morbidities and therapeutic targeting of these cells is a key aim. In a recent study, Katsuumi et al. found that targeting sodium-glucose co-transporter 2 (SGLT2) promoted immune clearance of senescent cells via programmed cell death-1 ligand (PD-L1) suppression, thus promoting immunosurveillance. This could have profound implications for many age-related diseases, including cancer and frailty.
The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.
Research summary
The paper addresses the targeting of senescent cells, which is a key aspect of longevity research as it relates to the underlying mechanisms of aging and age-related diseases. The findings regarding sodium-glucose co-transporter 2 (SGLT2) and its role in promoting immune clearance of senescent cells suggest a potential therapeutic avenue for mitigating the effects of aging. However, while the research presents solid findings, it does not introduce a major breakthrough or transformative approach, thus limiting its overall impact.
Author of this paper? Send a correction.